INSULET CORP
PODDNASDAQTrading Snapshot
- Day Range
- $131.54 – $134.98
- 52-Week Range
- $126.40 – $354.88
- Volume
- $5.48B
- Avg Volume
- $4.75B
- Shares Outstanding
- 69.3M
- Next Earnings
- Nov 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $2.71B
- Last Q Revenue
- $802M
- P/E Ratio
- 25.4
- P/S Ratio
- 3.1x
- EPS (TTM)
- $5.42
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −4.6%
Why Investors Own PODD
- ✓High-growth profile — revenue up +55.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 71% gross margin and 21% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
INSULET CORP
PODD
StockOtter · stockotter.spaceAbout INSULET CORP
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum
Insulet (NASDAQ: PODD) Chief Operating Officer Eric Benjamin said the company remains focused on expanding adoption of automated insulin delivery, or AID, systems across large and underpenetrated diabetes markets, while
Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at Bernstein Insi
California State Teachers Retirement System Has $2.22 Billion Stock Position in Insulet Corporation $PODD
California State Teachers Retirement System grew its holdings in shares of Insulet Corporation (NASDAQ: PODD) by 13,901.9% in the undefined quarter, according to the company in its most recent disclosure with the Securit
Insulet Corporation $PODD Stock Position Raised by Amundi
Amundi increased its holdings in shares of Insulet Corporation (NASDAQ: PODD) by 13.6% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The